Nesbuvir is primarily investigated for its antiviral properties, particularly in the treatment of hepatitis C virus (HCV) infections. It functions as a non-nucleoside inhibitor targeting the HCV RNA-dependent RNA polymerase, a crucial enzyme for viral replication. By inhibiting this enzyme, Nesbuvir effectively reduces the viral load in infected patients. Its application is often explored in combination therapies with other antiviral agents to enhance efficacy and reduce the likelihood of drug resistance. Research continues to evaluate its potential in improving treatment outcomes for patients with chronic hepatitis C, especially in cases where other treatments have failed or are unsuitable.